KyungDong Pharm home
Prescription Medicines

Losazol CR Cap. 100mg

Product Category
Peripheral blood flow disorder treatment
Active Ingredients
Cilostazol
Appearance
A hard capsule with a white cap and body, containing white or pale yellow granules.
Reimbursement Code
648104360
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
Of 1 capsule
- Active ingredients:
Cilostazol (in-house specification) ----- 100.0mg
- Other additives: Methacrylic acid/methyl methacrylate copolymer (1:2), microcrystalline cellulose, magnesium stearate, citric acid, ethyl cellulose, carrageenan, capsule, polysorbate 80

2. Effectiveness
1. Improvement of ischemic symptoms such as ulcers, pain, and cold sensation caused by chronic arterial occlusion (Buerger's disease, obstructive arteriosclerosis, diabetic peripheral angiopathy, etc.)
2. Inhibition of recurrence after cerebral infarction (excluding cardiogenic cerebral embolism)

3. Dosage and dosage
Cilostazol is usually administered orally at 200 mg once a day for adults.
This medicine should be taken on an empty stomach, avoiding meals.

4. Precautions for use
1. Warning
Since the pulse rate may increase due to the administration of cilostazol and angina may develop, a careful inquiry should be conducted regarding symptoms of angina (chest pain, etc.) (In a test examining the effect of suppressing the recurrence of cerebral infarction, the effect of significantly increasing PRP (pressure rate product) over a long period of time was recognized. In addition, a case of angina pectoris was found in the cilostazol administration group.)

2. Do not administer to the following patients.
1) Patients with bleeding (hemophilia, capillary fragility, intracranial hemorrhage, upper digestive tract hemorrhage, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.) or with such predispositions (active peptic ulcer, hemorrhagic stroke within the past 6 months, surgical operation within the past 3 months, proliferative diabetic retinopathy, uncontrolled hypertension) (there is a risk of promoting bleeding)
2) Patients with congestive heart failure (there is a risk of worsening symptoms)
3) Patients with a history of hypersensitivity to this drug or its components
4) Pregnant women, women who may be pregnant, and lactating women (refer to the ‘Administration to pregnant and lactating women’ section)

3. Administer with caution to the following patients.
1) Patients taking anticoagulants (warfarin, etc.), antiplatelet drugs (aspirin, ticlopidine, etc.), thrombolytics (urokinase, alteplase, etc.), prostaglandin E1 agents and their derivatives (alprostadil, limaprost alfadex, etc.)
2) Patients undergoing menstruation (there is a risk of promoting bleeding)
3) Patients with complications of coronary artery stenosis (administration of this drug may cause angina due to increased pulse rate).
4) Patients with severe renal failure (creatinine clearance ≤ 25 mL/min) (blood concentration of metabolites of this drug may increase) (see ‘Others’ section)
5) Patients with moderate or severe liver failure (blood concentration of this drug may increase) (see ‘Others’ section)
6) Patients with diabetes or impaired glucose tolerance (prone to developing adverse hemorrhagic symptoms)
7) Patients with high blood pressure whose blood pressure is continuously rising (malignant hypertension, etc.)
8) Patients with atrial or ventricular displacement, patients with atrial fibrillation or flutter, patients with ventricular tachycardia, ventricular fibrillation, or multifocal ventricular ectopic beats, and patients with prolonged QT interval.
9) Patients with or at risk for S-shaped ventricular septum (especially elderly people)
: Left ventricular outflow tract obstruction was reported in a patient with sigmoid ventricular septum. Monitor for new systolic murmurs or cardiac symptoms after starting cilostazol.

4. Adverse reactions
○ Information collected from sustained-release capsules
In clinical trials in which this drug, a sustained-release capsule, was administered to patients with chronic arterial occlusion, most of the adverse reactions reported after administration of this drug were adverse reactions known in the approval requirements for general tablets or were minor adverse reactions. Among these, the incidence of adverse reactions for which a causal relationship with the drug cannot be ruled out was 10 cases in 7 patients (6.9%), as follows.
A. Nervous System: Headache
B. Digestive System: Diarrhea
c. Cardiac system: atrial fibrillation, palpitations
D. Musculoskeletal system: joint swelling, limb pain
E. Systemic and administration site abnormalities: Chest discomfort
Serious adverse reactions reported include chronic renal failure, atrial fibrillation, hypopituitarism, hypoglycemia, syncope, large cell lung cancer, esophageal cancer, and implantable cardioverter-defibrillator malfunction, all of which had no causal relationship with the drug.
○ Information collected from general tablets
1) Serious adverse reactions
(1) Bleeding tendency: Bleeding tendencies such as intracranial hemorrhage such as cerebral hemorrhage (early symptoms: headache, nausea/vomiting, impaired consciousness, hemiplegia, etc.), pulmonary hemorrhage, sometimes subcutaneous hemorrhage, and rarely, digestive tract hemorrhage, epistaxis, fundus hemorrhage, and hematuria may occur. In these cases, stop administration and take appropriate measures.
(2) Blood system: Pancytopenia, agranulocytosis, and rarely thrombocytopenia, leukopenia, and aplastic anemia may occur, so observe thoroughly. If abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
(3) Interstitial pneumonia: Interstitial pneumonia accompanied by fever, cough, difficulty breathing, abnormal chest X-ray, and eosinophilia may occur. In such cases, discontinue administration and take appropriate measures, such as administration of corticosteroids.
(4) Congestive heart failure, myocardial infarction, angina pectoris, ventricular tachycardia, etc. may occur, so if abnormalities are recognized, administration should be stopped and appropriate measures should be taken.
(5) Jaundice and sometimes elevations of AST, ALT, ALP, LDH, etc. may occur, so observe thoroughly. If abnormalities are recognized, discontinue administration and take appropriate measures.
2) Other adverse reactions
(1) Hypersensitivity reaction: Photosensitivity reaction, sometimes rash, rarely rash, hives, and itching may occur. In these cases, discontinue administration.
(2) Whole body: Back pain, infection, chills, discomfort, neck stiffness, pelvic pain, and retroperitoneal hemorrhage may occur.
(3) Circulatory system: Arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardia, supraventricular tachycardia, supraventricular extrasystoles, and ventricular extrasystoles, decreased blood pressure, postural hypotension, sometimes palpitations, tachycardia, burning sensation, and rarely, increased blood pressure may occur. In these cases, take appropriate measures, such as reducing the dosage or stopping the dosage. Although the causal relationship has not been determined, cerebral infarction, cerebral ischemia, cardiac arrest, myocardial ischemia, syncope, varicose veins, and vasodilatation have been reported in clinical trials. Left ventricular outflow tract obstruction (frequency unknown※)
(4) Mental nervous system: Anxiety, neuralgia, asthenia, strange dreams, occasional headaches, dizziness, insomnia, numbness, and rarely drowsiness and tremors may occur. In these cases, take appropriate measures, such as reducing the dosage or stopping the dosage.
(5) Digestive system: stool abnormalities, indigestion, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophagitis, increased γ-GTP, gastritis, gastroenteritis, gum bleeding, melena, digestive ulcer, periodontal abscess, stomach ulcer, tongue edema, sometimes abdominal pain, nausea/vomiting, loss of appetite, diarrhea, heartburn, and abdominal bloating may occur.
(6) Blood and lymphatic system: Polycythemia, purpura, increased bleeding time, thrombocytopenia, eosinophilia, and rarely anemia may occur.
(7) Metabolism and nutritional system: facial edema, peripheral edema, gout, hyperlipidemia, and in rare cases, increased blood sugar levels may occur.
(8) Musculoskeletal system: Muscle pain, joint pain, bone pain, and bursitis may occur.
(9) Respiratory system: Increased cough, pharyngitis, rhinitis, asthma, sinusitis, and pneumonia may occur.
(10) Endocrine system: Diabetes may occur.
(11) Skin and appendages: Dry skin, swelling, and skin enlargement may occur.
(12) Sensory system: Amblyopia, blindness, double vision, ear pain, and rarely tinnitus and conjunctivitis may occur.
(13) Urogenital system: Proteinuria, cystitis, vaginal bleeding, vaginitis, and rarely, frequent urination may occur.
(14) Kidney: Renal failure, renal dysfunction, and in rare cases, elevations in BUN, creatinine, and uric acid may occur.
(15) Others: Occasionally sweating, swelling, chest pain, rarely pain, malaise, and fever may occur.
※: In case of voluntary reporting or adverse reactions occurring overseas, the frequency is indicated as unknown.
3) Domestic re-examination results of cilostazol general tablets
As a result of a safety evaluation conducted on 650 cases during the post-marketing surveillance period in Korea, the occurrence rate of adverse reactions was reported to be 38 out of 34 cases (5.24%), regardless of causal relationship. Among these, the occurrence rate of adverse reactions for which a causal relationship with drugs cannot be ruled out is 33 out of 29 cases (4.47%), as follows.
A. Central and peripheral nervous system abnormalities: headache 2.77% (18 cases/650 cases), anxiety (excitement) 0.15% (1 case/650 cases)
B. Gastrointestinal abnormalities: Diarrhea 0.46% (3 cases/650 cases), nausea 0.31% (2 cases/650 cases), dyspepsia 0.15% (1 case/650 cases), vomiting 0.15% (1 case/650 cases), anorexia 0.15% (1 case/650 cases), abdominal pain 0.15% (1 case/650 cases)
c. Abnormalities in skin and appendages: pruritus 0.15% (1 case/650 cases), rash 0.15% (1 case/650 cases)
D. Mental nervous system abnormalities: mild 0.15% (1 case/650 cases)
E. Heart rate abnormality: palpitations 0.15% (1 case/650 cases)
Among these, unexpected new adverse reactions not listed in the current approval were 0.15% (1/649 people, 1 case) of skeletal abnormalities and increased sputum production, regardless of causal relationship with the drug, and 0.15% (1/649 people, 1 case) of serious adverse reactions were vomiting, skeletal abnormalities, and bleeding, respectively, regardless of causal relationship.
4) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989-2015), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Sensory system: decreased sensation

5. General precautions
1) Administration of cilostazol to patients with cerebral infarction begins after the symptoms of cerebral infarction have stabilized.
2) When administering to patients with cerebral infarction, caution must be taken regarding interactions with other antiplatelet agents, and at the same time, administration to patients with persistent hypertension must be done with caution, and blood pressure must be sufficiently controlled during administration.
3) If an excessive increase in pulse rate occurs during cilostazol administration in a patient with complications of coronary artery stenosis, there is a possibility of causing angina, so in such cases, appropriate measures such as reducing the dose or discontinuing the administration should be taken.
4) Patients should be reminded to promptly report any signs that indicate early onset of blood disease, such as bleeding, light bruising, fever, and sore throat. If infection is suspected or there are clinical signs of a blood disorder, a complete blood count should be performed. If there are clinical or laboratory signs of hematologic abnormalities, administration of this drug should be discontinued immediately.
5) Cilostazol may cause dizziness, so caution should be advised before driving or operating machinery.
6) Taking this drug with food may increase the blood concentration of this drug and increase the incidence of adverse reactions. Therefore, it is recommended that the drug be administered on an empty stomach and that the time interval between meal and drug administration be 3 hours. In particular, when 200 mg of this drug was administered as a single dose after a high-fat meal, absorption increased compared to fasting administration, and Cmax increased by 100% and AUC increased by 40%, so be especially careful in patients eating a high-fat meal.
7) Cilostazol is a drug that has PDE Ⅲ inhibitory action. In foreign countries, in a placebo-controlled long-term comparative trial targeting patients with congestive heart failure (NYHA classification Ⅲ to Ⅳ) of inotropic drugs with PDE Ⅲ inhibitory effects, there were reports that the survival rate for inotropic drugs with PDE Ⅲ inhibitory effects was lower than that of placebo. Additionally, in patients without congestive heart failure, the prognosis of long-term administration of PDE III inhibitors, including cilostazol, is unclear.
8) In a trial examining the effect of suppressing cerebral infarction recurrence, there were more cases of onset and worsening of diabetes in the cilostazol group than in the placebo group (11/520 cases in the drug group, 1/523 cases in the placebo control group).
9) No tests have been conducted on the cerebral infarction seizure inhibition effect of cilostazol for asymptomatic cerebral infarction.

6. Interaction
1) Cilostazol is mainly metabolized by liver metabolic enzymes CYP3A4 and some CYP2D6 and CYP2C19.
2) Anticoagulants (warfarin, etc.), antiplatelet agents (aspirin, ticlopidine, etc.), thrombolytics (urokinase, alteplase, etc.), prostaglandin E1 agents and their derivatives (alprostadil, limaprost, alfadex, etc.) have the risk of promoting bleeding, so they should be used while sufficiently conducting blood coagulation tests.
3) Concomitant use with CYP3A4 inhibitors or CYP2C19 inhibitors (cimetidine, diltiazem, erythromycin, ketoconazole, lansoprazole, itraconazole, miconazole, omeprazole, HIV-1 protease inhibitors, etc.) may increase the blood concentration of this drug and increase its effectiveness. When using together, caution should be exercised, such as reducing the dose or starting from a low dose. Also, be careful not to take it at the same time as grapefruit juice.
4) Concomitant use with drugs that are CYP3A4 or CYP2C19 substrates (cisapride, midazolam) may increase the blood concentration of this drug and increase the effect. When using together, caution should be exercised, such as reducing the dose or starting from a low dose.
5) Because this drug may have an additional hypotensive effect due to reflex tachycardia, caution is required when using it in combination with drugs that have the potential to lower blood pressure or vasodilators that cause reflex tachycardia, such as dihydropyridine calcium channel blockers.
6) There is an overseas report that when 100 mg of cilostazol and 80 mg of the HMG-CoA reductase inhibitor lovastatin were co-administered, the AUC of lovastatin increased by 64% compared to lovastatin administered alone.
7) Ketoconazole, erythromycin, omeprazole: When administered in combination with 400 mg of ketoconazole, a CYP3A4 inhibitor, Cmax increased by 94% and AUC by 117%, and when administered in combination with 500 mg of erythromycin, Cmax increased by 47% and AUC by 73%. When administered in combination with omeprazole, a CYP2C19 inhibitor, the metabolite 3,4-dehydro-cilostazole increased by 69%.)

7. Administration to pregnant and lactating women
1) In animal experiments (rats), an increase in abnormalities, low birth weight, and death were reported, so do not administer to pregnant women or women who may be pregnant.
2) In animal experiments (rats), transfer to milk was reported, so stop breastfeeding during administration.

8. Administration to children
Safety for low birth weight infants, newborns, infants, infants, or children has not been established (there is little experience with use).

9. Administration to elderly people
In general, elderly people have reduced physiological function, so they should be careful about reducing their intake.

10. Treatment in case of overdose
There is limited information on acute overdose of this drug in humans. Symptoms and signs of acute overdose are expected to include severe headache, diarrhea, hypotension, tachycardia, or cardiac arrhythmias. Monitor patients carefully and provide supportive and supportive treatment. Because this drug is highly protein bound, effective removal through hemodialysis or peritoneal dialysis will be difficult. The stomach must be emptied through appropriate vomiting or gastric lavage. The oral LD50 of this drug is >5.0 g/kg in mice and rats, and >2.0 g/kg in dogs.

11. Pharmaceutical equivalence test information Note 1
A. As a result of measuring cilostazol in the blood of 66 people (fasting) and 60 people (postprandial), 1 capsule each was administered orally on an empty stomach and after a meal to healthy adults in a 2x2 cross-over study of the test drug Pressil extended-release capsule 100 mg (cilostazol) (Colmar Pharma Co., Ltd.) and the control drug Pretal extended-release capsule (cilostazol) [Korea Otsuka Pharmaceutical Co., Ltd.]. When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log0.8 to log1.25, demonstrating biological equivalence.
*Table: refer to manual

B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted for the test drug Presil extended-release capsule 200 mg (cilostazol) [Colma Pharma Co., Ltd.] with the reference drug Presil extended-release capsule 100 mg (cilostazol) [Colmar Pharma Co., Ltd.], and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
Note 1. This drug was manufactured by Colmar Pharma Co., Ltd. with the entire process using the same raw materials as Cilostazol Extended-Release Capsule 100 mg (Cilostazol) and Cilostazol Extended-Release Capsule 200 mg (Cilostazol), using the same manufacturing method.

12. Others
1) In vivo kinetics of patients with renal dysfunction: When 100 mg of cilostazol tablets per day were administered orally for 8 consecutive days to patients with severe renal impairment, the Cmax of this drug decreased by 29% and AUC by 39% compared to healthy adults, but the Cmax of the active metabolite increased by 173% and AUC by 209%. There was no significant difference in mild and moderate patients. Administer with caution to patients with severe renal dysfunction.
2) Body dynamics in patients with liver dysfunction: When 100 mg of cilostazol tablets was administered orally as a single dose to patients with mild liver dysfunction, the blood concentration did not show any difference from that of healthy adults (Cmax decreased by 7%, AUC increased by 8%). Administer with caution to patients with moderate or severe liver function impairment.
3) In a 13-week and 52-week repeated oral administration toxicity test using beagles, thickening of the left ventricular endocardium and coronary artery dysfunction were recognized at high doses. The non-toxic doses were 30 mg/kg/day and 12 mg/kg/day, respectively, but these changes were not recognized in rats and monkeys. In the case of beagles, changes in the left ventricular endocardium, right atrium epicardium, and coronary artery were observed in a cardiotoxicity test administered intravenously for 1 week, and in monkeys, mild hemorrhagic changes in the left ventricular endocardium were recognized. Cardiotoxicity in animals has also been recognized for other PDE inhibitors and vasodilators, and there are reports that toxicity occurs particularly easily in dogs.
4) In SHR-SP (stroke-prone spontaneously hypertensive rats), which are genetically prone to stroke due to persistently significantly high blood pressure, survival time was recognized to be shorter in the 0.3% mixed diet group compared to the control group (average lifespan: 40.2 weeks in the Xantro group, 43.5 weeks in the control group).

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 capsules/bottle, 500 capsules/bottle

7. Period of use
36 months from date of manufacture